The benzocaine market was valued at USD 120.9 Mn by 2019. The growing incidence of acute pain complications worldwide primarily drives the benzocaine market growth. Furthermore, the growing incidence of premature ejaculation increases the demand for benzocaine products throughout the globe.

Benzocaine belongs to a class of benzoic acid esters which is a topical anesthetic agent that acts by preventing the transmission of impulses along the nerve fibers and the nerve endings. It binds to sodium channels and reverses the stability of neuronal membranes which decreases its permeability to sodium ions. It is currently available as over the counter products (OTC), like gels, ointments, creams, etc.

The major segments related to the benzocaine market are: 

By Clinical Application (2017–2027; US$ Mn)

Topical Anesthesia

Premature Ejaculation

Others

By Distribution Channel (2017–2027; US$ Mn)

Hospital Pharmacy

Retail Pharmacy

Others

Geography Segment (2017–2027; US$ Mn)

North America

U.S.
Canada

Europe

United Kingdom
Germany
Russia
France
Italy
Spain
Ukraine
Rest of Europe

Asia Pacific

China
Japan
Rest of Asia Pacific

Latin America (LATAM)

Brazil
Mexico
Rest of Latin America

Middle East and Africa (MEA)

GCC
Rest of MEA 

Justification for study?

• The intention of the study is to give a comprehensive outlook of the global benzocaine market
• The overall segmentation of the benzocaine market, by clinical application, distribution channel, and geography is minutely studied. Topical Anesthesia and hospital pharmacy are dominating the clinical application and distribution channel segments respectively
• Rising prevalence of acute pain worldwide
• Significant increase in the number of clinical trial investigation for determining the therapeutic efficacy and safety of benzocaine as a drug formulation for the treatment of premature ejaculation

Report gist?

• The study of the global benzocaine market includes qualitative analysis of factors such as drivers, restraints, and opportunities
• The report covers the qualitative and quantitative analysis of the overall market segmented on the basis of clinical application and distribution channel and categorization of the same at the geography level
• This research report presents the analysis of each segment from 2017 to 2027 in which 2019 is considered as the base year. The compounded annual growth rate is calculated for the respective segments from 2020 to 2027

The study includes the profiles of major market players with a significant global and regional presence along with top company positioning. 

Significant customers?

• This study is suitable for industry participants and stakeholders in the pharmaceutical manufacturers actively engaged in the production and marketing of benzocaine due to the  rising prevalence of acute pain worldwide
• The report will benefit researchers engaged in conducting a clinical trial investigation of benzocaine in the treatment of premature ejaculation
• Managers with financial institutions looking to publish recent and forecasted statistics pertaining to benzocaine market
• Financial institutions, venture capitalist, analysts, investors, government organizations, policymakers, regulatory authorities, researchers, looking for insights into the market to determine future strategies 

Segment Analysis

Topical anesthesia is representing the largest market share in the clinical application segment for the benzocaine market. Rising prevalence of acute pain complications associated with hemorrhoids, sunburns, toothache, etc. increases the demand for benzocaine drug formulations worldwide. According to the latest research information presented by the World Health Organization (WHO), the global prevalence rate associated with hemorrhoids is 4.4%. It is also used for the treatment of oral ulcers and ear pain. Premature ejaculation will be garnering comfortable market growth during the forecast period owing to the rising prevalence of premature ejaculation worldwide. According to the latest statistics presented by the National Institute of Health (NIH), the prevalence rate associated with premature ejaculation is 19.5% across the globe. Certain condoms are manufactured using benzocaine in order to inhibit the sensitivity of the penis and prolong the erection time by delaying the ejaculation.

Hospital pharmacy is presently dominating the distribution channel segment for the benzocaine market. The severe drug-related adverse events associated with benzocaine drug formulations such as skin blistering, irritation make it imperative for the accurate drug compounding under the supervision of a hospital pharmacist. It is expected that in the near future retail pharmacy will be showcasing exemplary market performance owing to the flourishing generic drugs market and ability to cater to medicinal requirements of households residing in the remote locations.

North America is spearheading the geography segment for the benzocaine market. Rising prevalence of acute pain complications requiring topical anesthesia primarily drives the benzocaine market growth in the region. As per the latest research citings provided by the Center for Disease Control and Prevention (CDC), approximately 33.8% of the adult population in the United States reported being suffering from sunburn. Affordable reimbursement scenario associated with the use of benzocaine as topical anesthesia further accentuates the market growth in the region. Europe is considered as the second-largest regional segment for the benzocaine market owing to the domicile of key players such as Merck KGaA., Reckitt Benckiser Healthcare, Septodont, Krka Pharma, etc propels the market growth in the region. The Asia Pacific is anticipated to be the fastest-growing regional segment for the benzocaine market on account of the rising prevalence of hemorrhoids across all age groups and flourishing generic drugs market.